Quin-C7
Based on 1 Customer Validation
Quin-C7 is an orally active FPR2/ALX antagonist. Quin-C7 binds to the orthosteric ligand-binding pocket of FPR2/ALX, modulates receptor activation, and inhibits pro-inflammatory ERK signaling mediated by serum amyloid A (SAA). Quin-C7 reduces pro-inflammatory mediators TNF-α levels, increases anti-inflammatory IL-10, decreases inflammatory neutrophils and pro-inflammatory M1 macrophages, downregulates ERK1/2 phosphorylation, and upregulates JNK1/2/3 phosphorylation. Quin-C7 blocks FPR2/mFpr2 signaling, reduces brain lesion volume. Quin-C7 can be used for the research of inflammatory bowel disease and neuromyelitis optica spectrum disorder.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.76%
- CAS 番号: 871100-12-8
- 分子式: C25H25N3O4
- 分子量:431.48
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
MAPK Compound Library
HY-L010
-
Neuronal Signaling Compound Library
HY-L013
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Macrophage Related Compound Library
HY-L174
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
生物活性
|
ERK1 |
ERK2 |
JNK1 |
JNK2 |
JNK3 |
IL-10 |
Quin-C7 binds with high affinity to human FPR2/ALX, forming a network of polar and stacking interactions with receptor residues, including a unique hydrogen bond with Q2586.52[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Quin-C7 (16-32 mg/kg; i.g.; daily; 4 days) significantly reduces pathology in NMOSD mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N (male, SPF grade, 7-8 weeks old, body weight 21 g, DSS-induced acute colitis)[1]
-
Dosage:0.512 mg/kg; 2.56 mg/kg; 12.8 mg/kg; 64 mg/kg; 320 mg/kg; 16 mg/kg; 160 mg/kg
-
Administration:i.g.; daily; 7 days
-
Result:Reduced weight loss and decreased Disease Activity Index (DAI) compared to vehicle-treated colitis mice.
Showed an ED50 for symptomatic amelioration (DAI loss) was 2.2110 mg/kg, and ED50 for weight recovery was 1.1430 mg/kg.
Reduced colonic tissue damage, immune cell infiltration, and histopathological scores compared to vehicle-treated colitis mice.
Reversed DSS-induced colon shortening compared to vehicle-treated colitis mice.
Reduced colonic TNF-α levels, increased colonic IL-10 levels, and reduced colonic myeloperoxidase (MPO) and Ly6G levels compared to vehicle-treated colitis mice.
Reduced splenic neutrophil (CD45+ CD11b+ Ly6G+) fractions, reduced colonic neutrophil fractions and median Ly6G fluorescence intensity, and reduced colonic F4/80+ CD86+ (M1 macrophage) cell fractions compared to vehicle-treated colitis mice.
Decreased phosphorylation levels of colonic ERK1/2 and increased phosphorylation levels of colonic JNK1/2/3 compared to vehicle-treated colitis mice.
Showed no significant change in colonic p38 phosphorylation.
-
Animal Model:C57BL/6 (8-10 weeks of age; NMOSD induced by intracerebral infusion of AQP4-IgG and human complement)[2]
-
Dosage:16 mg/kg; 32 mg/kg
-
Administration:i.g.; daily; 4 days
-
Result:Significantly reduced loss of AQP4, GFAP, and MBP, and brain lesion volume at 32 mg/kg/day.
Reduced the absolute number of B cells and NK cells in the spleen, and the absolute number of microglia and infiltrating CD4+ T cells in the brain.
Increased the percentage of microglia expressing anti-inflammatory factors IL-10 and TGF-β.
Decreased the percentage of microglia expressing pro-inflammatory factors IL-6 and TNF-α.
化学情報
-
CAS 番号 871100-12-8
-
性状 Solid
-
分子量 431.48
-
分子式 C25H25N3O4
-
Color White to off-white
-
SMILES
CCCCOC1=CC=C(C(NN2C(C3=CC=C(C=C3)O)NC4=CC=CC=C4C2=O)=O)C=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 100 mg/mL (231.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.59 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Yang WS, et al. Oral FPR2/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease. Acta Pharmacol Sin. 2025;46(7):1958-1973. [Content Brief]
[2]. Qi C, et al. Targeting formyl peptide receptor 2 to suppress neuroinflammation in neuromyelitis optica spectrum disorder. Theranostics. 2025;15(10):4495-4506. Published 2025 Mar 19. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3176 mL | 11.5880 mL | 23.1760 mL | 57.9401 mL |
| 5 mM | 0.4635 mL | 2.3176 mL | 4.6352 mL | 11.5880 mL | |
| 10 mM | 0.2318 mL | 1.1588 mL | 2.3176 mL | 5.7940 mL | |
| 15 mM | 0.1545 mL | 0.7725 mL | 1.5451 mL | 3.8627 mL | |
| 20 mM | 0.1159 mL | 0.5794 mL | 1.1588 mL | 2.8970 mL | |
| 25 mM | 0.0927 mL | 0.4635 mL | 0.9270 mL | 2.3176 mL | |
| 30 mM | 0.0773 mL | 0.3863 mL | 0.7725 mL | 1.9313 mL | |
| 40 mM | 0.0579 mL | 0.2897 mL | 0.5794 mL | 1.4485 mL | |
| 50 mM | 0.0464 mL | 0.2318 mL | 0.4635 mL | 1.1588 mL | |
| 60 mM | 0.0386 mL | 0.1931 mL | 0.3863 mL | 0.9657 mL | |
| 80 mM | 0.0290 mL | 0.1449 mL | 0.2897 mL | 0.7243 mL | |
| 100 mM | 0.0232 mL | 0.1159 mL | 0.2318 mL | 0.5794 mL |
Quin-C7 関連分類
HY-W668775 関連分類
Powered by Bioz